Max Mednik
  • Home
  • About
  • Interests
    • Angel investing
    • Magic
    • Scuba Diving
  • Blog
  • Contact

Readings and musings

Why I invested in Visual Labs

7/23/2018

0 Comments

 
Picture
I’m really excited to have been able to invest in Visual Labs. Based in Menlo Park, Visual Labs is the body camera company that does not make body cameras. With technology designed by Stanford University computer science graduates, Visual Labs provides “body worn computer” solutions that are hardware-agnostic for police, private security, and sports teams. Their focus is on superior software with unique, critical functionality such as live streaming, real-time location tracking, and analytics.

The company was started by a founder who went to my high school (and college) and who has pursued this vision since his senior project. He has built out a complex product with multiple interworking components and interfaces, and it’s actually being used in production in many police departments and even in this year’s Super Bowl. Having a smartphone (which also happens to have a camera) provides many advantages over a more clunky/dedicated/proprietary hardware device and allows the Visual Labs software to keep improving over time and providing more critically useful functionality to police and security teams worldwide.

I’m personally excited about the company because I believe this sort of focus on software is much more scalable as a business and effective for the end-user over the long run. I love seeing a team work tirelessly over years to get a product out and adopted in the field (especially in difficult, demanding use cases like police/security). I also think the company has a strong positive impact on the safety and effectiveness of the officers who serve our community.

Here is recent press coverage on the company:
CBS, ABC, Fox, Ars Technica, Police Mag

What I love:
  • Technical founder passionate about his vision
  • Built strong engineering team
  • Product built out and working well in real-world use cases
  • Great quotes and feedback from customers
  • Good traction

Risks:
  • Long, tricky sales cycle dealing with government clients
  • Potential business model scalability issues
  • Market domination by bigger competitors
0 Comments

Why I invested in Respirix

6/8/2018

0 Comments

 
Picture
I’m really excited to have been able to invest in Respirix. Based in San Francisco, Respirix is a healthcare company on a mission to revolutionize cardiac monitoring. Respirix is developing a novel approach using software and hardware to measure hemodynamic parameters (that currently require expensive and invasive implants) at low cost and non-invasively. The technology has wide potential, but they are initially focused on bringing a game-changing monitor for congestive heart failure (CHF) patients to market that will allow their physicians to monitor them remotely and help prevent dangerous and expensive hospitalizations.

Heart disease is something I personally care about because it’s impacted my family directly in the past: several of my grandparents and pets died from heart disease (and some specifically CHF). Now, there are many companies chasing heart failure -- it is a very big market. Every year in the United States, about one million CHF patients are hospitalized for what is called “decompensation” (fluid retention in the body and lungs); the estimated cost of these hospitalizations in the U.S. for 2010 was $39.2 billion, and that number is forecasted to reach $70 billion by 2030. Importantly, over 50% of CHF patients are readmitted to the hospital within 6 months of discharge.

Today, there is only one FDA-approved device for CHF patients to monitor their status at home. It’s an implant that costs $18,000 and gets placed permanently inside the pulmonary artery in the heart through a surgical procedure. Despite these challenges, this technology was acquired for $455 million before selling a single device when it was demonstrated that the daily measurements it provided could predict decompensation in advance and allowed physicians to have patients take medication that reduced CHF hospitalizations by 38% in a 470 patient trial.

Now, imagine that instead of having a chip placed inside your heart for life, you simply had to breathe into a sensor and get the same analysis of your condition. Sounds amazing, right? That is precisely what Respirix is doing. Respirix’s approach involves using precise analysis of breath exhalation (proprietary signal along with machine learning) to monitor changes in pressure caused by the pulmonary vasculature, which may be a more sensitive indication of pulmonary artery compliance.

So far, the Respirix team has accomplished a number of important milestones, including building over twenty of their Cardiospire devices, acquiring animal model data, starting multiple clinical trials, winning grants, and recruiting a strong team and advisors.

If successful, Respirix’s first product would make it a lot less invasive and easier for CHF patients to have their health monitored at home. I know startup risks are large and the probability of success is generally low, but Respirix has a differentiated approach and has gotten very solid results to date, and they are tackling a huge market opportunity. That being said, I like that the CEO has a lot of personal skin in the game and cares passionately about seeing the Respirix solution become reality. I’m proud to have invested alongside Synergy Ventures, Signatures Capital, Theranova, and StartX.

I’m personally excited about the company because given my family history, I recognize that there is a strong need for new technologies to treat heart disease more effectively, at lower cost, and with increased patient access.

What I love:
  • Founder with lots of personal skin in the game
  • Built strong scientific, engineering, and advisory team
  • Multiple patents filed
  • Good progress on device development and clinical trials
  • Good feedback from experts

Risks:
  • Difficult, long, expensive, risky process to get to FDA approval
  • Full product technology value proposition still not entirely proven out
  • Need to get physicians on board to promote and incorporate it into their practices
0 Comments

Why I invested in Contraline

5/25/2018

0 Comments

 
Picture
I’m really excited to have been able to invest in Contraline. Based in Charlottesville, Virginia, Contraline is a medical device company developing the first long-lasting, non-hormonal, and reversible male contraceptive.

The company was started by a founder (fellow immigrant!) who is passionate about giving men more options and responsibility in contraception. He wrote essays to get into college about the lack of a male birth control pill and has been working tirelessly to recruit a strong team of scientists with an actual lab and tangible progress towards clinical trials. If successful, the product would be game-changing, and I acknowledge the risks are very large and probability of success low. I like that the founder is so committed to seeing his vision turn into reality. I’m proud to have invested alongside Jason Calacanis, Mike Savino, LAUNCH, Founders Fund, FundRx, and Abstract Ventures.

I’m personally excited about the company because the options for men are indeed very limited (either not very effective or permanent and painful). 73% of couples in the world rely on female partners for contraception. I believe the societal and social impact from giving men more options and responsibility would greatly benefit gender relations and couple dynamics overall. And I like that there are defensible scientific advances at the core of this technology that have the chance to be executed upon by a good team.

Couples and physicians can register their interest in Contraline here:
http://www.contraline.com/participate

Here is recent press coverage on the company:
TechCrunch, WMRA

What I love:
  • Immigrant founder maniacal about his vision
  • Built strong scientific team
  • 8 patents filed
  • Actual running operations in a lab, making good progress through milestones
  • Product is differentiated from competition

Risks:
  • Difficult, long, expensive, risky process to get to FDA approval
  • Full product technology value proposition still not entirely proven out
  • Need to get physicians on board to promote and incorporate it into their practices
0 Comments
<<Previous

    Archives

    June 2021
    May 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    April 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    May 2019
    March 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    February 2018
    January 2018
    November 2017
    October 2017
    September 2017
    May 2017
    April 2017
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011
    April 2011
    March 2011
    February 2011
    January 2011
    December 2010
    November 2010
    October 2010
    September 2010
    August 2010
    July 2010
    June 2010
    May 2010
    April 2010
    March 2010
    February 2010

    Categories

    All
    Angel Investing
    Cacti
    Cars
    China
    Community Service
    Culture
    Design
    Djing
    Dogs
    Education
    Entertainment
    Entrepreneurship
    Family
    Finance
    Food
    Google
    Happiness
    Incentives
    Investment Banking
    Judaism
    Law
    Lighting
    Magic
    Marketing
    Medicine
    Networking
    Nolabound
    Philosophy
    Professionalism
    Psychology
    Reading
    Real Estate
    Religion
    Romance
    Sales
    Science
    Shangri-La
    Social Entrepreneurship
    Social Media
    Sports
    Teams
    Technology
    Travel
    Turtles
    Ucla
    Venture Capital
    Web Services
    Weddings
    Zen

    Subscribe

    RSS Feed

Picture
Picture
  • Home
  • About
  • Interests
    • Angel investing
    • Magic
    • Scuba Diving
  • Blog
  • Contact